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ABSTRACT: As a continuation of our previous report on the cytostatic activity for 
several halogenated thieno[3,2-d]pyrimidines, subsequent in vitro evaluation of the 
corresponding halogenated pyrrolo[3,2-d]pyrimidines identified compounds 1 and 2 with 
antiproliferative activity against three different cancer cell lines. Upon screening of a 
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series of pyrrolo[3,2-d]pyrimidines, the 2,4-Cl compound 1 was found to exhibit 
antiproliferative activity in the lower micromolar concentrations. However introduction 
of iodine at C7 resulted in significant enhancement of potency by reducing the IC50 into 
sub-micromolar levels, thereby suggesting the importance of the halogen at C7. This 
finding was further supported by a markedly lower activity for 3, which lack the 2,4-Cl 
substituents but an increased antiproliferative effect again when 3 was substituted by an 
halogen at C7 (4). Cell-cycle and apoptosis studies conducted on the two potent 
compounds 1 and 2 showed differences in their activity, wherein compound 1 induced 
accumulation of the G2/M stage in triple negative breast cancer MDA-MB-231 cells with 
little evidence of apoptotic death while compound 2 robustly induced apoptosis of MDA-
MB-231 cells concomitant with G2/M cell cycle arrest. 
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Introduction 
Pyrrolopyrimidines exist as two regioisomers, specifically pyrrolo[2,3-d]pyrimidine 
and pyrrolo[3,2-d]pyrimidine and are more commonly referred to as 7-deazapurine and 9-
deazapurine respectively (Figure 1).1 Due to a close resemblance to the purines, the 
pyrrolopyrimidine scaffold has found pharmacological utility as a purine isostere. 2-13 The 
7-deazapurines (Figure 1a) are naturally occurring and widely used in drug design 
primarily due to their propensity to be ribosylated. Echiguanine B and Tubercidin are two 
examples of naturally occurring 7-deazapurines exhibiting anticancer properties (Figure 
1a). 
Figure 1: Deazapurines and their biological properties. 
 
 In contrast, the pyrrolo[3,2-d]pyrimidines do not occur naturally and must be 
synthetically prepared. The 9-deazapurines have been explored in the past as nucleoside 
isosteres (Figure 2b)8 and these efforts have resulted in the design of purine nucleoside 
phosphorylase (PNP) inibitors8,14-23, dihydrofolate reductase (DHFR) inhibitors1,24 and 
more recently for kinase inhibition (Figure 2b).25-27  
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Figure 2: Exploration antiproliferative activities of halogenated fused pyrimidines. 
 
Our laboratory’s interest in exploring the biological properties of fused heterocyclic 
compounds28-32 has resulted in the identification of antiproliferative properties of 
halogenated thieno[3,2-d]pyrimidines (Figure 2a). The halogenated thieno[3,2-
d]pyrimidines were found to induce apoptosis in L1210 cells independent of cell cycle 
arrest. However, they showed remarkable differences in their cytotoxic mechanisms in 
the triple negative breast cancer (TNBC) cell line MDA-MB-231. In this cell model, cell 
death was accompanied by dramatic arrest at the G2/M transition, but only in the 
analogue lacking bromine at C7 (Figure 2a, right).33 In an effort to further explore these 
findings with an alternate scaffold, we opted to synthesize the analogous series of 
halogenated pyrrolo[3,2-d]pyrimidines. Once in hand, the toxicity of each pyrrolo[3,2-
d]pyrimidine was then tested against three cancer cell lines (L1210, CEM and HeLa). 
This examination revealed significant antiproliferative activities for compounds 1-4 
(Figure 2b) but also indicated that this function was enhanced by inclusion of iodine at 
C7. Subsequent testing of compounds 1 and 2 across the NCI-60 cancer cell line panel 
further supported the impact of iodine at C7 on the cytostatic/cytotoxic activity of 
halogenated pyrrolo[3,2-d]pyrimidines. The consequences of halogenated pyrrolo[3,2-
d]pyrimidines 1 and 2 were then evaluated on cell cycle distributions and apoptosis of 
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MDA-MB-231 cells to explore their mechanism of antiproliferative activity. The results 
indicated that both compounds trigger arrest at G2/M, and this and other findings will be 
discussed herein.  
 
Results and Discussion 
Chemistry. In order to explore the antiproliferative properties of the halogenated 
pyrrolo[3,2-d]pyrimidines as well as the effect of the halogen at C7, two sets of 
compounds were synthesized (Schemes 1 and 2). The target compounds in Scheme 1 
were used to explore the anticancer properties of the pyrrolo[3,2-d]pyrimidines with a 
chlorine at C4. A second set of compounds illustrated in Scheme 2 possess O-benzyl 
groups on the C2 and C4 positions. These compounds, which are also intermediates in the 
syntheses of the corresponding 2'-deoxy-9-deaza-nucleosides, were tested against cancer 
cell lines concurrent with the testing of the halogenated pyrrolo[3,2-d]pyrimidines in 
Scheme 1. This latter exercise helped indentify the impact of halogens on the anticancer 
properties of pyrrolo[3,2-d]pyrimidines. Finally the corresponding C-nucleosides (Figure 
3) reported previously by our group34 were also examined for their antiproliferative 
properties.  
The synthesis of halogenated pyrrolo[3,2-d]pyrimidines (Scheme 1) began with  
chlorination of the known pyrrolo[3,2-d]pyrimidin-2,4-dione 535-39. Preparation of the 
sodium salt, followed by heating with phenylphosphonic dichloride (PhPOCl2) at 170-
175 ˚C gave 1 in a 60% yield.35-39 Iodination of 1 using N-iodisuccinimide (NIS) in 
tetrahydrofuran (THF) at room temperature yielded the iodo analogue 2 in a 54% yield.40 
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Attempts to protect the 5-NH of 2 with tert-butoxycarbonyl (Boc) in order to evaluate the 
effect of the NH on the biological activity of 2 failed due to the instability of the Boc 
protecting group during the subsequent silica gel purification. Alternatively, Boc 
protection of 1 was attempted using Boc2O in the presence of 4-dimethylaminopyridine 
(DMAP) at room temperature to give 6 in 65% yield.41 Iodination of pyrrolo[3,2-
d]pyrimidin-2,4-dione 5 by NIS in DMF followed by crystallization from ethanol gave 7 
in 87% yield.42 Next, 7-iodo pyrrolo[3,2-d]pyrimidin-2,4-dione 7 was protected with the 
methoxymethyl (MOM) group by addition of MOMCl to a stirred solution of 7 and 60% 
sodium hydride (NaH) suspension under an inert atmosphere, which resulted in 8 with all 
the three NH groups MOM protected in a 40% yield.  
Scheme 1: Synthesis of halogenated pyrrolo[3,2-d]pyrimidines. 
 
In addition to the compounds shown in Scheme 1, several bis-O-benzylated 
pyrrolo[3,2-d]pyrimidines were synthesized (Scheme 2) in order to evaluate the impact of 
the iodine at C7 on the cytostatic properties of the pyrrolo[3,2-d]pyrimidines in the 
absence of the C4 chloro group. The 2,4–bis-O-benzylated compounds were chosen for 
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this evaluation due to the facile synthesis and our past experience with these compounds 
for the preparation of 2'-deoxy-9-deaza-nucleosides via Heck coupling.34  
 As shown in Scheme 2, synthesis of the bis-O-benzylated pyrrolo[3,2-d]pyrimidines  
was initiated by formylation of the 6-methyl group on 9 by heating with DMF-
dimethylacetal in DMF at 60-65 °C, to obtain 10 in 70% yield (Scheme 2).37 Subsequent 
ring cyclization using Batcho-Leimgruber pyrrole methodology was accomplished by 
stirring 10 with zinc (Zn) in acetic acid (AcOH) to give 2,4-OBn pyrrolo[3,2-
d]pyrimidine 3 in 90% yield.37,43-45 Iodination of 3 using NIS in methylene chloride 
(CH2Cl2) afforded 4 in 90% yield. Protection of 5-NH using Boc in the presence of 
DMAP afforded 11 in 53% yield.34 
Scheme 2: Synthesis of the bis-O-benzyl analogues. 
 
Along with compounds in Scheme 1 and Scheme 2, three additional compounds, 
namely 2-[(dimethylamino)methyleneimino]-4-benzyloxy-5H-pyrrolo[3,2-d]pyrimidine 
12 and 9-deaza-2ˊ-deoxynucleosides 13 and 14 (Figure 3) were also tested. While 12 
helped evaluate the effect of a substituent other than OBn at C2, the C-nucleosides34 13 
and 14 were tested owing to past2-8,46-56 and recent57 interest in the pharmacological 
properties of 9-deazanucleosides. The syntheses of compounds shown in Figure 3 have 
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been reported by our group but their antiproliferative properties had not been previously 
evaluated.34,58  
Figure 3: Intermediate 12 and 9-deaza-2'-deoxynucleosides 13 and 14.34 
 
 
In vitro cell growth inhibition. The cytotoxic activities of several compounds 
described above were first assessed in three cultured tumor cell models: L1210, a mouse 
lymphocytic leukemia cell line59, CCRF-CEM60, an acute lymphoblastic leukemia cell 
line, and HeLa, a human cancer cell line derived from a human cervical 
adenocarcinoma.61-62 Comparisons of resolved IC50 values (Table 1) indicate that the 
dichloro compounds 1 and 2 show measureable cytostatic activity in all three tumor cell 
lines. The presence of iodine at C7 on the 2,4-dichloro pyrrolo[3,2-d] (2) increases the 
antiproliferative activity by a factor of 5 to 20, when compared to 1. A analogues increase 
in cytotoxicity for bis-O-benzylated pyrrolo[3,2-d]pyrimidine (3) was observed upon 
introduction of C7 iodine (4). Replacement of the 2,4-chloro moieties with O-benzyl 
groups led to a loss of activity by a factor of 3-15, however the activity of 4 was 
comparable to 1. This suggests a compensation for the loss of activity for the O-benzyl 
groups by the presence of iodine at C7.  
Introduction of the Boc group on 2,4-dichloro pyrrolo[3,2-d]pyrimidine 6 did not lead 
to any loss in activity against CEM and HeLa cells, while activity against L1210 was 
weakened by a factor of 3. On the other hand, the presence of the Boc group on the bis-
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O-benzyl analogue (11) led to a complete loss in activity. These data support: a) the 
importance of 7-NH in the cytostatic role of the 2,4-O-benzylated analogues (3 and 4) 
and b) a potentially different mode of action for the 2,4-O-benzylated analogues as 
compared to 2,4-dichloro analogues (1 and 2). Additionally, replacement of the 2-O-
benzyl on 3 with the aminovinyl dimethylamine group of 1234 led to a marginal loss of 
activity indicating that an OBn group at C2 is not crucial for cytostatic activity and can be 
replaced. In order to evaluate the effect of the C7 iodine, the iodo analogue of 12 was 
sought, however all attempts at iodination failed due to the presence of 5-NH.34 The 
ketone or amide groups, as found in 5, 7 and 8, do not impart activity against any cancer 
cell line tested, which is consistent with our previous studies on the thieno[3,2-
d]pyrimidines. Similarly, the C-nucleosides 13 and 14 were both inactive and exhibited 
no cytotoxicity.34 However, an interesting discovery resulting from examining various 
intermediates was the very modest cytotoxicity observed for the 2,4-bis-O-benzyl-5-
nitro-6-dimethylaminovinyl pyrimidine (11).  
Table 1: Anti-tumor cell activity of test compounds. 
 
Compound A B R1 R2 R3 X 
IC50* (µM) 
L1210 CEM HeLa 
1 Cl Cl - - H H 6.8 ± 2.8 25 ± 2 19 ± 3 
2 Cl Cl - - H I 0.93±0.0 4.9±0.4 0.92±0.04 
3 OBn OBn - - H H 118±8 86±22 98±14 
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4 OBn OBn - - H I 21 ± 2 17 ± 4 17 ± 0 
5 O O H H H H >250 >250 >250 
6 Cl Cl - - Boc H 21±1 26±2 18±3 
7 O O H H H I >250 >250 >250 
8 O O MOM MOM MOM I >250 >250 >250 
10 OBn OBn - - -¶ -¶ 74±49 59±41 100±38 
11 OBn OBn - - Boc I 247 ± 4 193 ± 81 72 ± 47 
1237 OBn  - - H 
H 170 ± 24 164 ± 68 126 ± 32 
1334 O O H H H 
 
>250 >250 >250 
1434 O NH2 - H H  
>250 >250 >250 
5FU - - - - - - 0.33 ± 0.17 18 ± 5 0.54 ± 0.12 
*50% inhibitory concentration. 5FU- 5-fluoro Uracil. ¶ See Scheme 2 for structure. 
 
NCI-60 DTP Human Tumor Cell Line Screen. Cytostatic/toxic activities of the 
2,4-dichloro pyrrolo[3,2-d]pyrimidines 1 and 2 were tested at 10 µM concentrations 
against the NCI-60 DTP Human Tumor Cell Line screen. These cell lines are derived 
from many different cancer types including leukemia, non-small cell lung cancer 
(NSCLC), colon, CNS cancer, melanoma, ovarian, renal, prostate, and breast cancer 
(Figure 4). In this screen, 10 µM of each compound is added to cells and incubated for 48 
hrs before chemical fixation and measurement of cellular protein content using the 
sulphorhodamine B (SRB) dye. This assay enables differentiation between cytostatic and 
cytotoxic activities based on the magnitude and direction of endpoint deviations from 
initial cell density.63 Compound 1 did not show meaningful inhibition of growth of the 
cancer cell lines at 10 µM concentration (Figure 4) however introduction of iodine at C7 
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(compound 2) led to an increase in the ability of the halogenated pyrrolo[3,2-
d]pyrimidine to inhibit the growth of all cancer cell lines tested. The results of single-
dose testing suggests that compound 2 predominately exhibits cytostatic activity (growth 
percent 0-50%), but in some instances led to a cytotoxic effect (growth percent <0%). 
The latter was observed in HL-60(TB), NCI-H522, COLO 205, MDA-MB-435, 
OVACAR-3, UO-31 and DU-145 (Figure 4). These results, in addition to the earlier 
testing, verify that the iodine at C7 plays a key role in increasing the potential anticancer 
properties of the C7-iodinated compound 2.   
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Figure 4: Growth Inhibition of cancer cell lines by 1 and 2 at 10 µM. 
 
Compound 1 and 2 tested at 10µM concentration against NCI-60 DTP Human Tumor Cell Line Screen. The 
blue bar indicates growth percent of cell line upon incubation with 1 at 10 µM, and the red bar indicates cell 
line upon incubation with 2 at 10 µM. The number on each bar indicates the % growth.  
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Cell cycle and apoptosis studies. Previously, 2,4-dichloro thieno[3,2-d]pyrimidines (see 
Figure 2a) were shown to induce apoptosis independent of cell cycle arrest in L1210 
cells. Our recent findings show that 2,4-dichloro thieno[3,2-d]pyrimidine can induce cell 
cycle arrest at G2/M in the MDA-MB-231 breast cancer cell line. Subsequently, we 
chose to study the effects of 2,4-dichloro pyrrolo[3,2-d]pyrimidines 1 and 2 on cell cycle 
progression and apoptosis in MDA-MB-231 cells. MTT cytotoxicity assays resolved IC50 
values of 6.0 ± 1.3 μM and 0.51 ± 0.10 μM for compounds 1 and 2, respectively, in 
MDA-MB-231 cell cultures (Figure 5). These data provided dosage information critical 
for subsequent cell cycle and apoptosis assays, but also further confirm that introduction 
of iodine at C7 increases the potency by at least a factor of 10.  
 
 
Figure 5. MTT assays for cytotoxicity by 1 and 2 in MDA-MB-231 cells. Cells were treated with select 
concentrations of compounds 1 (a) and 2 (b). After 48 h, cell viability was measured using MTT assays. 
Compound cytotoxicity was calculated by non-linear regression to a sigmoidal dose response function.  
Quoted IC50 values represent the mean ± SD of three independent experiments.   
 
 To determine whether the anticancer activities of pyrrolo[3,2-d]pyrimidine 
compounds 1 and 2 are associated with perturbation of the cell cycle, we monitored the 
effects of each compound on cell cycle distributions using propidium iodide staining and 
flow cytometry. At the IC80 concentration of 15 µM, compound 1 induced profound 
accumulation of the tumor cells at the G2/M stage after 48 hours (Figure 6a), consistent 
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with mitotic arrest and similar to the effect of the non-brominated 2,4-dichloro 
thieno[3,2-d]pyrimidine (Figure 2a, left) on MDA-MB-231 cells reported previously.64 
By contrast, treatment with an equitoxic concentration (1.75 µM) of compound 2 yielded 
a much smaller but still statistically significant enrichment in the G2/M fraction (Figure 
6b, P = 0.0006 vs. vehicle control). The similarities in IC50 and the accumulation of the 
tumor cells in the G2/M phase observed for compound 1 and the non-brominated 
thieno[3,2-d]pyrimidine described previously64 suggests that they may induce MDA-MB-
231 tumor cell death via similar mechanisms. However, the dramatic enhancement in 
IC50 observed with compound 2 concomitant with its decreased impact on the cell cycle 
suggests that introduction of iodine at C7 might induce cytotoxicity by a distinct 
molecular mechanism. That such an impact might be directed by the iodine group on C7 
is also supported by the abrogation of G2/M accumulation that was observed when 2,4-
dichloro thieno[3,2-d]pyrimidine was brominated at the same site (Figure 2a, right).64 
 
Figure 6. Cell cycle analyses of MDA-MB-231 cells following treatment with 1 and 2. Cells were treated 
with IC80 concentrations of compound 1 (a, 15 µM) or compound 2 (b, 1.75 µM) for 48 h.  The cell cycle 
distributions of drug-treated cells and vehicle (DMSO) controls were analyzed by flow cytometry of fixed, 
propidium iodide-stained cells. A minimum of 3000 cells were analyzed per cell population. Each bar 
represents the mean ± SD across 4 independent cell samples.  
 
Next, we analyzed unfixed MDA-MB-231 cell samples by staining with annexin 
V and 7-amino-actinomycin D (7-AAD) to determine whether pyrrolo[3,2-d]pyrimidine 
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compounds 1 and 2 direct cell death using classical apoptotic or necrotic mechanisms.  
Vehicle (DMSO)-treated cells yielded very low proportions of apoptotic or necrotic cells 
after 48 h (Figure 7a). Curiously, treating cells with IC80 concentrations (15 µM) of 
compound 1 only slightly increased the proportion of cells recovered in early/late 
apoptosis (Figure 7b, d). By contrast, over 40% of MDA-MB-231 tumor cells treated 
with compound 2 at its IC80 (1.75 µM) were annexin V-positive after 48 h, with the larger 
proportion of these 7-AAD negative consistent with early apoptosis (Figure 7c, d). While 
compound 1 is clearly toxic to MDA-MB-231 cells at the tested concentration, only a 
modest (although statistically significant) increase in annexin V-positive cells was 
detected.  There are several possibilities that could account for this, including: (i) that cell 
lysis occurs rapidly following induction of apoptosis by compound 1, preventing 
significant accumulation of annexin V-positive bodies, or (ii) that a distinct (i.e., non-
apoptotic/necrotic) cell death pathway is triggered by 1. On the other hand, the robust 
accumulation of annexin V-positive cells observed following treatment with compound 2  
is consistent with apoptotic cell death in a manner that is similar to the effects that were 
previously observed for the thieno[3,2-d]pyrimidine compounds shown in Figure 2a.33  
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Figure 7. Apoptosis analyses of MDA-MB-231 cells following treatment with IC80 concentrations of 
compounds 1 and 2.  Cells were treated with (a) an equal volume of vehicle (DMSO), (b) 15 µM compound 
1, or (c) 1.75 µM compound 2.  After 48 h, cells were stained using annexin V and 7-AAD and analyzed by 
flow cytometry. A minimum of 10,000 cells were analyzed per condition, and subdivided into four 
categories: non-apoptotic/necrotic (bottom left), early apoptotic (bottom right), late apoptotic/necrotic (top 
right), and necrotic (top left). Percentages of total cells detected in each quadrant are indicated.  (d) Total 
apoptotic (early + late) cell fractions detected in each treatment group.  Bars show the mean ± SD values 
compiled across four independent experiments.  
 
Discussion. Halogenated pyrrolo[3,2-d]pyrimidines have been commonly used as key 
intermediates to install a variety of functional groups on a pyrrolo[3,2-d]pyrimidine 
scaffold  in order to evaluate the effect of substituents for a variety of medicinal 
properties. 26-27,39-40,42 However, the potential of halogenated pyrrolo[3,2-d]pyrimidines 
themselves as a therapeutically relevant scaffold has not previously been evaluated. 
Prompted by our earlier findings with the thieno[3,2-d]pyrimidines33, 2,4-
dichloropyrrolo[3,2-d]pyrimidines 1 and 2 were evaluated for their antiproliferative 
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properties against a number of cancer cell lines (Table 1 and Figure 2). Since, the 
importance of the C4 Cl group was already established33, we studied the effect of pyrrole 
on the antiproliferative properties of an halogenated fused-pyrimidine scaffold. The 
activity of 2,4-dichloro pyrrolo[3,2-d]pyrimidine 1 is slightly lower than its thieno 
counterpart, however, the presence of 7-iodo enhanced the cytotoxicity to an extent that 
the activity was comparable to the halogenated thieno[3,2-d]pyrimidines shown in Figure 
2. This notable increase in cytotoxic activity for 2 led to evaluation of bis-O-benzylated 
pyrrolo[3,2-d]pyrimidines 3 and 4 to assess the effect of C7 iodine independent of the C2 
and C4 chlorines. The enhancement of cytotoxic activity for both 2 and 4 compared with 
the C7-unsubstituted parent compounds highlights the ability of the C7 iodine in 
imparting cytotoxic properties to the pyrrolo[3,2-d]pyrimidine scaffold independently 
warranted a detailed study of 2,4-substituted pyrrolo[3,2-d]pyrimidines possessing C7-
iodine. 
Our recent studies on 2,4-dichlorothieno[3,2-d]pyrimidines have shown that the 
presence of a bromine at C7 brought about complete alteration of the G2/M cell cycle 
arrest-induced tumor cell death to cell cycle-independent death in MDA-MB-231 cells.64 
Similarly, cell cycle distribution experiments conducted on pyrrolo[3,2-d]pyrimidines 1 
and 2 indicated that both induce G2/M cell cycle arrest even though the presence of the 
C7 iodine marginally diminished the G2/M cell cycle arrest. Furthermore, apoptosis and 
necrosis studies revealed that compound 2 elicited a robust early stage apoptosis, but the 
same was not observed for compound 1, which lacks the C7 iodine. Although intriguing, 
the difference in activity for compounds 1 and 2 follows a pattern that is similar to what 
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had been observed for the halogenated thieno[3,2-d]pyrimidines wherein the presence of 
an halogen at C7 alters the antiproliferative mechanism.  
In summary, the antiproliferative activities of the halogenated-fused pyrimidines 
highlight the potential of reactive species as therapeutically useful scaffolds. Previously 
these types of covalent modifiers had been considered undesirable65-72 due to their 
chemically labile nature, however the renewed interest in such compounds73-75 have 
shown they may be exploited to treat cancer in a novel and effective manner.    
Conclusions. We have identified interesting antiproliferative properties for several 
2,4-dichloro pyrrolo[3,2-d]pyrimidines with emphasis on the ability of C7 iodine in 
markedly enhancing their cytotoxicity. These studies highlight their pharmacological 
relevance in addition to expanding the domain of the halogenated fused [3,2-d]pyrimidine 
scaffold. These halogenated compounds exhibited potent activity against triple negative 
breast cancer MDA-MB-231 cells by arresting the cell cycle in G2/M. We have 
previously established the importance of C4-Cl, however herein we have demonstrated 
the effect the halogen at C7 has on the potency and G2/M cell cycle-induced tumor cell 
death. Studies are underway to further expand the repertoire of these molecules with 
varied substituents on the scaffold to improve the antiproliferative activities of 
halogenated pyrrolo[3,2-d]pyrimidines. These results will help expand the chemical 
space of halogenated heterocyclic compounds with an ability to induce death in cancer 
cells.    
 
Experimental. All chemicals and reagents listed in this section were purchased through 
commercially available sources unless otherwise noted. All reactions run in CH2Cl2, 
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CH3CN, and THF were obtained from a solvent purification system (SPS, Model: 
mBraun Labmaster 130). All reactions run in anhydrous DMF, MeOH and pyridine were 
obtained from Sigma–Aldrich or Acros Organics. All 1H and 13C NMRspectra were 
obtained from a JEOL ECX 400 MHz NMR. All 1H and 13C NMR spectra were 
referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are 
indicated by the symbols s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q 
(quartet), m (multiplet), and br (broad). All NMR solvents were obtained from 
Cambridge Isotope Laboratories. All reactions were monitored by thin layer 
chromatography (TLC) on 0.25 mm precoated glass plates. All column chromatography 
was run on 32–63 µ silica gel obtained from Dynamic Adsorptions Inc. (Norcross, GA, 
USA). Melting points are uncorrected. Yields refer to chromatographically and 
spectroscopically (1H and 13C NMR) homogeneous materials. All mass spectra (MS) 
were recorded and obtained from the University of Maryland Baltimore County Mass 
Spectrometry Facility and Johns Hopkins Mass Spectrometry Facility. 
 
Pyrrolo[3,2-d]pyrimidin-2,4-dione (5): To a stirred slurry of (E)-6-(2-
(dimethylamino)vinyl)-5-nitropyrimidin-2,4-dione 435,38 (1g, 4.4 mol) in fresh glacial 
AcOH (50 mL), Zinc dust (stabilized) (2 g) was added in two lots of 1g with an interval 
of 1 h. Upon overnight stirring the yellow slurry changed to a pale yellow to off-white 
slurry which was filtered and the filtrate concentrated in vacuo to obtain brown syrup. 
The product was precipitated from the brown syrup using ethanol to obtain 4 as white 
solid (0.6 g, 89.8%). The spectral data agrees with reported data.38 1H NMR (400 MHz, 
DMSO-d6): δ 5.82-5.83 (t, 1H, J=2.28 Hz), 7.12-7.13 (t, 1H, J=2.72 Hz, J=2.96 Hz), 
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10.57 (s, 1H), 10.74 (s, 1H), 11.82 (s, 1H). 13C NMR (400 MHz, DMSO-d6): δ 96.5, 
110.9, 127.4, 135.1, 152.0, 156.3. 
2,4-Dichloropyrrolo[3,2-d]pyrimidine (1): To pyrrolo[3,2-d]pyrimidin-2,4-dione 5 
(2.00 g, 13.2 mmol), 1N NaOH (15 mL), and 0.60 g NaOH in 15 mL H2O was added and 
the mixture stirred at 40 °C until a clear solution was obtained. The solution was cooled 
to room temperature (21-25 °C) and then placed in an ice bath to obtain thick slurry. The 
slurry was then filtered to obtain a pale yellow solid. The solid was dissolved in 1N 
NaOH (15 mL), and heated to 40 °C to obtain a clear solution that upon cooling provided 
white crystals. The crystals were washed with MeOH (20 mL) and acetone (20 mL), and 
then dried under vacuum. The dry solids were taken in phenylphosphonic dichloride (10 
mL) and heated to 170-175 °C for 5 h during which the reaction mixture became a 
brown-black solution. After 5 h the hot reaction mixture was poured onto ice, extracted 
with EtOAc (200 mL) and the organic layer washed with sat. NaHCO3 solution (3 X 100 
mL) till all effervescence subsided. The organic layer was then washed with brine and 
dried over MgSO4. The organic layer was concentrated in vacuo and loaded onto silica. 
The product was purified using column chromatography eluting with 9:1 then 3:1 
hexanes/ EtOAc to obtain 1 as an off-white solid (1.50 g, 7.9 mmol, 60%). Rf 0.5 in 3:1 
hexanes/EtOAc. Mp 228.3-232.0 °C. 1H NMR (400 MHz, DMSO-d6): δ 6.71 (d, 1H, J = 
3.2 Hz), 8.09 (d, 1H, J = 2.8 Hz), 12.75 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 
103.2, 124.3, 138.0, 143.5, 149.6, 153.9. ESI-MS m/z for C6H3Cl2N3 calculated [M+H]+ 
187.9776, found 187.9777.  
7-iodo-2,4-dichloro pyrrolo[3,2-d]pyrimidine (2): To a solution of 2,4-dichloro 
pyrrolo[3,2-d]pyrimidine 1 (100 mg, 0.53 mmol) in anhydrous THF (5 mL), NIS (144 
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mg, 0.64 mmol) was added under N2 atmosphere and stirred for 2 h after which TLC 
indicated consumption of 1. The solvent was removed in vacuo and the residue dissolved 
in EtOAc. The organic phase was washed with aq. solution of Na2S2O3 followed by 
water, brine and then dried over MgSO4. The organic layer was concentrated in vacuo 
and loaded on silica. The product was purified using column chromatography eluting 
with 9:1 hexanes/EtOAc to obtain product as off-white solid (90 mg, 54%). Rf 0.55 in 3:1 
hexanes/EtOAc. Mp decomposed from 160-230 °C. Spectral data agrees reported data.40 
1H NMR (400 MHz, DMSO-d6): δ 8.29 (s, 1H), 13.19 (s, 1H, NH). 13C NMR (400 MHz, 
DMSO-d6): δ 58.2, 124.4, 140.9, 143.5, 149.8, 153.5. ESI-MS m/z for calculated [M+H]+ 
313.8743, found 313.8740. 
N-tert-butyloxycarbonyl-2,4-dichloro pyrrolo[3,2-d]pyrimidine (6): To a mixture of 
of 2,4-dichloro pyrrolo[3,2-d]pyrimidine 1 (50 mg, 0.26 mmol), di-tert-butyl carbonate 
(116 mg, 0.53 mmol) and DMAP (6.5 mg, 0.053 mmol), anhydrous THF (5 mL) was 
added under N2 atmosphere and stirred overnight upon which TLC indicated 
consumption of 1. The reaction mixture was concentrated and loaded on silica. The 
product was purified using column chromatography eluting with 49:1 hexanes/EtOAc to 
obtain product as white solid (50 mg, 65%). Rf 0.5 in 19:1 hexanes/EtOAc. Mp 101.0-
103.2 °C. 1H NMR (400 MHz, DMSO-d6): δ 1.66 (s, 9H), 6.71-6.72 (d, 1H, J=3.68 Hz), 
8.01-8.02 (d, 1H, J=3.68 Hz). 13C NMR (400 MHz, DMSO-d6): δ 28.0, 87.2, 106.6, 
123.4, 137.3, 146.5, 147.0, 153.1, 158.1. ESI-MS m/z for C11H11Cl2N3O2 calculated 
[M+H]+ 288.0301, found 288.0301 (2x35Cl), 289.0335 (2x35Cl, 13C), 290.0272 (35Cl 
37Cl). 
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7-Iodo-pyrrolo[3,2-d]pyrimidine-2,4-dione (7): Pyrrolo[3,2-d]pyrimidine-2,4-dione 5 
(500 mg, 3.31 mmol) was suspended in anhydrous DMF (10 mL) under N2 atmosphere 
and cooled to -10 to -5 °C. To this slurry, N-iodosuccinimide (894 mg, 3.97 mmol) was 
added and the mixture stirred for 2 h at -10 to -5 °C, at which point the DMF was 
removed in vacuo to provide a brown sticky solid. The product was crystallized from the 
residue using 50% EtOH (6 mL) to give 7 (800 mg, 87.2%) as a yellow solid. Mp >300 
°C.  1H NMR (400 MHz, DMSO-d6): 7.31 (s, 1H), 10.64 (br s, 1H), 10.76 (br s, 1H), 
11.07 (br s, 1H). 13C NMR: 93.5, 111.8, 131.7, 136.9, 151.8, 155.7. FAB-MS for 
C6H4IN3O2 calculated M+ 276.9348, found 276.9345, calculated [M+H]+ 277.9421, 
found 277.9419. 
7-Iodo-1,3,5-tris-methoxymethyl-1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-dione (8): 
A solution of 5 (200 mg, 0.72 mmol) in anhydrous DMF (5 mL) was cooled on ice under 
N2 atmosphere to which 60% suspension of NaH in oil (130 mg, 3.25 mmol) was added 
and stirred for 15 min. The ice was removed and the mixture stirred at room temperature 
for an additional 15 min at which point CH3OCH2Cl (0.19 mL, 2.53 mmol) was added 
dropwise over 15 min. The reaction mixture was stirred for 30 min on ice after which 
water (5 mL) was added followed by extraction with CH2Cl2. The organic layer was 
washed with brine and dried over MgSO4. The organic layer was concentrated in vacuo 
and loaded on silica. The product was purified using column chromatography eluting 
with 9:1 and 4:1 hexanes/EtOAc to obtain product 8 as off-white solid (178 mg, 60%). Rf 
0.5 in 3:1 hexanes/EtOAc. Mp 143.5-148 °C. 1H NMR (400 MHz, CDCl3): 3.22 (s, 3H), 
3.30 (s, 3H), 3.34 (s, 3H), 5.32 (s, 2H), 5.53 (s, 2H), 5.55 (s, 2H), 7.10 (s, 1H).13C NMR: 
28.2, 45.2, 56.5, 56.7, 58.0, 72.5, 78.4, 111.6, 134.6, 136.9, 152.2, 154.4. FAB-MS for 
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C12H16IN3O5 calculated M+ 409.0134, found 409.0127, calculated [M+H]+ 410.0207 
found 410.0201. 
2,4-Bis-benzyloxy-5-nitro-6-dimethylaminovinyl pyrimidine (10): To a solution of 
2,4-Bis-O-Benzyl-6-methyl-5-nitro pyrimidine 937 (2.3 g, 6.5 mmol) in DMF (20 mL), 
DMF-dimethyl acetal (1.74 mL, 13 mmol) was added at room temperature under N2 
atmosphere. The reaction was lowered in a preheated oil bath at 60-65 ° C and stirred 
overnight upon which TLC indicated absence of starting material. The solvents were 
removed and the residue loaded on silica. The product was purified using column 
chromatography eluting with 9:1 hexanes/EtOAc to obtain product 10 as orange-yellow 
solid (2 g, 75%). Rf 0.5 in 3:1 hexanes/EtOAc. Spectral data agrees with reported data.37 
1H NMR (400 MHz, CDCl3): δ 2.87-2.94 (br d, 6H), 5.33-5.36 (d, 1H, J=12.36 Hz), 5.38 
(s, 2H), 5.44 (s, 2H), 7.31-7.41 (m, 10H), 7.98-8.01 (d, 1H, J=12.36 Hz). 13C NMR (400 
MHz, CDCl3): δ 68.9, 69.5, 87.9, 127.5, 128.0, 128.1, 128.3 128.5, 135.8, 136.6, 151.8, 
160.7, 161.6, 163.5. FAB-MS for C22H22N4O4 calculated [M+H]+ 407.1714, found 
407.1717. 
2,4-Bis-benzyloxy-5H-pyrrolo[3,2-d]pyrimidine34 (3): To a suspension of 2,4-Bis-O-
Benzyl-5-nitro-6-β-dimethylaminovinyl pyrimidine 10 (2 g, 4.9 mmol) in AcOH (40 ml), 
Zn (4 g) was added in lot of 2g with an interval of 4hrs. The reaction mixture was stirred 
overnight at room temperature during which a dark yellow suspension became pale 
yellow suspension. The reaction mixture was filtered and the filtrate concentrated in 
vacuo to obtain syrup which was dissolved in CH2Cl2 then washed with saturated aq. 
NaHCO3 followed by brine. The organic phase was dried over MgSO4 and loaded on 
silica. The product was purified using column chromatography eluting with 4:1 and 1:1 
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hexanes/EtOAc to obtain product as pale-yellow solid (1.45 g, 90%). Rf 0.3 in 1:3 
hexanes/EtOAc. Spectral data agrees with reported data.37 1H NMR (400 MHz, CDCl3): δ 
5.47 (s, 2H), 5.54 (s, 1H), 6.50-6.51 (dd, 1H, J=1.84, 2.28), 7.29-7.38 (m, 7H), 7.43-7.45 
(m, 2H), 7.52-7.53 (m, 2H), 8.41 (br s, 1H, NH). 13C NMR (400 MHz, CDCl3): δ 68.3, 
69.0, 102.6, 111.9, 127.8, 128.3, 128.4, 128.5, 128.6, 128.7, 128.8, 136.1, 137.3, 151.8, 
156.79, 159.7. FAB-MS for C20H17N3O2 calculated [M+H]+ 332.1394, found 332.1398. 
7-iodo-2,4-bis-benzyloxy-5H-pyrrolo[3,2-d]pyrimidine34 (4):To a stirred solution of 
2,4-bis-O-benzyl-5H-pyrrolo[3,2-d]pyrimidine 3 (1.43 g, 4.3 mmol) in anhydrous CH2Cl2 
(15 mL) under N2, NIS (1.069 g, 4.7 mmol) was added at which point the reaction 
mixture turned from pink to orange. The mixture was stirred overnight until the TLC 
indicated the absence of starting material. The reaction mixture was washed with aqueous 
Na2S2O3 (15 mL) followed by brine (15 mL). The organic layer was dried over MgSO4, 
loaded onto silica and purified using column chromatography eluting with 4:1 then 1:1 
hexanes/EtOAc to obtain 4 as a pale-yellow solid (1.77 g, 3.88 mmol, 90%).34 Rf 0.4 in 
1:3 hexanes/EtOAc. Mp 157.8-158.4 ˚C. 1H NMR (400 MHz, CDCl3): δ 5.53 (s, 4H), 
7.32 -7.41 (m, 9H), 7.55-7.57 (m, 2H), 8.71 (br s, 1H, NH). 13C NMR: 57.3, 68.7, 69.3, 
111.9, 127.9, 128.3, 128.6, 128.66, 128.7, 128.9, 132.4, 135.8, 137.2, 152.0, 156.9, 160.1. 
FAB-MS m/z for C20H16IN3O2 calculated [M+H]+ 458.0360, found 458.0357. 
2,4-Bis-benzyloxy-5-N-boc-7-iodopyrrolo[3,2-d]pyrimidine (11): To a solution of 7-
iodo-2,4-bis-benzyloxy-5H-pyrrolo[3,2-d]pyrimidine 4 (100 mg, 0.218 mmol) in dry 
THF (5 mL), Boc2O (96 mg, 0.437 mmol) and DMAP (145.33 mg, 0.0437 mmol) were 
added and the mixture stirred for 1 hr until TLC indicated the absence of starting 
material. The solvent was removed in vacuo and the residue purified by column 
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chromatography eluting with 49:1 hexanes/EtOAc to obtain 11 as a white solid (65.1 mg, 
116 mmol, 53.4%).34 Rf 0.5 in 19:1 hexanes/EtOAc. Mp 118.5-122.5 ˚C. 1H NMR (400 
MHz, CDCl3): δ 1.51 (d, 9H), 5.59 (s, 2H), 5.50 (s, 2H), 7.38-7.30 (m, 6H), 7.47 (d, 2H), 
7.56 (d, 2H), 7.91 (s, 1H). 13C NMR: δ 27.8, 64.3, 68.9, 69.5, 85.3, 110.9, 127.9, 128.4, 
128.5, 128.8, 136.2, 136.5, 136.9, 147.2, 156.6, 157.9, 161.1. FAB-MS m/z for 
C25H24IN3O4 calculated [M+H]+ 558.0884, found MH+ 558.0885. 
2-[(Dimethylamino)methyleneimino]-4-benzyloxy-5H-pyrrolo[3,2-d]pyrimidine (12): 
A slurry of 2-[(Dimethylamino)methyleneimino]-4-benzyloxy-5-nitro-6-β-
dimethylaminovinyl pyrimidin-4-one37 (3 g, 8.1 mmol) in EtOH (100 mL) and water (20 
mL) was heated to 90-95 °C and Na2S2O4 (8.5 g, 50.5 mmol) added in lots of 1.7 g after 
every 30-45 min. After 8.5 g, the slurry changed to pale yellow slurry and TLC indicated 
absence of starting material. The EtOH was removed in vacuo and the residual solids 
were extracted with CH2Cl2 (2X200 mL). The organic phase was washed with water, 
then dried over MgSO4. The organic phase was removed in vacuo to obtain 12 as pale 
yellow solid (1.7 g, 71%). Rf 0.45 in CH2Cl2/MeOH. Spectral data agrees with reported 
data.37 1H NMR (400 MHz, CDCl3): δ 2.99 (s, 3H), 3.04 (s, 3H), 6.22-6.24 (t, 1H, J=2.72 
Hz, J=2.32 Hz), 7.06-7.07 (t, 1H, J=3.2 Hz, J=2.76 Hz), 7.11-7.25 (m, 3H), 7.31-7.33 
(m, 2H), 9.68 (br s, 1H, NH).  13C NMR (400 MHz, CDCl3): δ 35.0, 40.9, 45.5, 102.1, 
115.2, 126.8, 127.6, 128.0, 128.2, 138.9, 144.4, 154.1, 156.0, 156.4. FAB-MS m/z for 
C16H17N5O calculated M+ 295.1433, found 295.14288. Calculated [M+H]+ 296.1506, 
found 296.1508. 
9-deaza-2'-deoxyxanthosine (13): White solid Mp 185.3-186.8 ˚C. 1H NMR (400 MHz, 
DMSO d6): δ 1.84-1.95 (m, 2H), 3.49-3.57 (m, 2H), 3.75 (br s, 1H), 4.19 (br s, 1H), 4.96 
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(d, 1H, J=3.24 Hz), 5.05 (dd, 1H, J=5.92 Hz, J=10.08 Hz), 5.62 (br s, 1H), 10.56 (br s, 
1H, NH), 10.58 (br s, 1H, NH), 11.67 (br s, 1H, NH). 13C NMR (400 MHz, DMSO d6): δ 
43.0, 62.7, 73.6, 73.7, 87.7, 111.2, 111.5, 125.2, 132.7, 151.8, 156.3. FAB-MS for 
C11H13N3O5 calculated M+ 267.0855, found 267.0853; calculated [M+H+] 268.0928 
found 268.0930. 
9-deaza-2'-deoxyguanosine (14): White solid Mp >300 ˚C. Rf 0.5 in 4:1 CH2Cl2: MeOH. 
1H NMR (400 MHz, DMSO d6): δ 1.86 (dd, 1H, J=5.26 Hz, J=12.62 Hz), 2.13 (td, 1H, 
J=5.04 Hz, J=11.69 Hz), 3.37 (ddd, 2H, J=4.12 Hz,  J=11.66 Hz, J=11.44 Hz), 3.69 (t, 
1H, J=4.12 Hz), 4.15 (br s, 1H), 4.85 (d, 1H, J=3.64 Hz), 5.05 (dd, 1H, J=5.28 Hz, 
J=10.76 Hz), 5.66 (br s, 2H, NH2), 5.81 (br s, 1H), 7.09 (d, 1H, J=3.2 Hz), 10.41 (br s, 
1H, NH), 11.33 (br s, 1H, NH). 13C NMR (400 MHz, DMSO d6): δ 42.6, 63.8, 73.6, 73.9, 
88.3, 113.8, 115.7, 126.1, 151.3, 155.4, 164.0.  ESI-MS m/z for C11H14N4O4 calculated 
[M+H+] 267.1087, found 267.1089. 
 
 
 
Cell proliferation assays: All assays were performed in 96-well microtiter plates. To 
each well were added (5−7.5) × 104 tumor cells and a given amount of the test 
compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) 
or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37 °C in a 
humidified CO2-controlled atmosphere. At the end of the incubation period, the cells 
were counted in a Coulter counter. The IC50 (50% inhibitory concentration) was defined 
as the concentration of the compound that inhibited cell proliferation by 50%. MDA-MB-
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231 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
plus 10% fetal bovine serum (FBS).  Cells were seeded in 96 well plates at 5 × 103 cells 
per well and treated with compounds 1 and 2 across a range of concentrations.  After 48 
h, relative numbers of viable cells were quantified using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) Cell Proliferation Assay kit (ATCC) according 
to the manufacturer’s instructions.  The fraction of viable cells relative to wells treated 
with vehicle alone was analyzed as a function of drug concentration using a sigmoidal 
dose response model with PRISM v3.03 software (GraphPad) to resolve IC50.  
 
Cell cycle distribution and apoptosis assays: The cell cycle distributions of MDA-MB-
231 cells treated with compounds 1 or 2 were analyzed using propidium iodide staining 
and flow cytometry.  2 × 106 cells were seeded in 100 mm dishes and treated with vehicle 
alone or compounds 1 or 2 at the IC80 values determined by cell viability assays.  48 h 
following treatment the cells were collected, fixed, and stained with propidium iodide 
(Sigma Aldrich) as described76 immediately before analysis by flow cytometry.  To 
analyze apoptotic cell death, MDA-MB-231 cells were seeded as described above but 
then treated with vehicle alone or compounds 1 or 2 at their IC80 concentrations of 15 
µM and 1.75 µM, respectively.  After 48 h, the cells were then collected and the cellular 
fractions undergoing early apoptotic, late apoptotic/necrotic, and necrotic cell death were 
measured by staining with Annexin V and 7-amino-actinomycin D (7-AAD) using the 
BD Pharmingen PE Annexin V Apoptosis Detection Kit I (BD Pharmingen) as 
described.77  All flow cytometry analyses required for cell cycle distribution and 
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apoptosis assays were performed at the University of Maryland Greenebaum Cancer 
Center Shared Flow Cytometry Facility. 
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